文献速递母胎医学产科

意大利北部产前人群性染色体非整倍体发生率:27年纵向研究

Incidence of sex chromosome aneuploidy in a prenatal population: 27-year longitudinal study in Northern Italy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

该研究分析了意大利北部1995至2021年共13 939 526例出生和231 227例侵入性产前诊断,检出933例性染色体非整倍体。2015年游离DNA(cfDNA)商业化应用后,侵入性操作频率显著下降(P=0.03),而产前性染色体非整倍体检出频率显著上升(P=0.007)。2016至2021年间,高风险cfDNA结果是31.4%检出的性染色体三体的指征,仅次于高龄妊娠。

要点

  • cfDNA应用后侵入性产前诊断频率显著下降(P=0.03)。
  • cfDNA应用后产前性染色体非整倍体检出频率显著上升(P=0.007)。
  • 2016至2021年,31.4%的性染色体三体由高风险cfDNA结果提示。

核心结论

  • 研究提示将性染色体非整倍体纳入产前cfDNA筛查可增加受累个体的产前诊断。
  • 随着早期确诊获益获得更多认可,医务人员需掌握关于相关表型差异及有效干预措施的综合循证信息。

研究设计与样本

  • 纵向研究,收集1995至2021年意大利公立和私立中心绒毛膜绒毛取样(CVS)和羊水样本的基因检测结果。
  • 染色体分析采用常规Q显带核型分析。
  • 采用回归分析和描述性统计评估产前诊断检测频率及性染色体非整倍体检出的趋势。

主要发现

  • 27年间记录出生13 939 526例,实施侵入性操作231 227例,产前诊断性染色体非整倍体933例。
  • 2015年cfDNA商业化应用后,侵入性操作频率显著下降(P=0.03)。
  • 2015年cfDNA商业化应用后,产前性染色体非整倍体检出频率显著上升(P=0.007)。
  • 2016至2021年,高风险cfDNA结果是31.4%检出的性染色体三体的指征,仅次于高龄妊娠。

临床怎么用

  • 研究提示将性染色体非整倍体纳入产前cfDNA筛查可增加受累个体的产前诊断。
  • 作者认为医务人员需掌握关于相关表型差异及有效干预措施的综合循证信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The availability of cell-free (cf) DNA as a prenatal screening tool affords an opportunity for non-invasive identification of sex chromosome aneuploidy (SCA). The aims of this longitudinal study were to investigate the evolution and frequency of both invasive prenatal diagnostic testing, using amniocentesis and chorionic villus sampling (CVS), and the detection of SCA in cfDNA samples from a large unselected cohort in Northern Italy. METHODS: The results of genetic testing from CVS and amniotic fluid samples received from public and private centers in Italy from 1995 to 2021 were collected. Chromosomal analysis was performed by routine Q-banding karyotype. Regression analyses and descriptive statistics were used to determine population data trends regarding the frequency of prenatal diagnostic testing and the identification of SCA, and these were compared with the changes in indication for prenatal diagnostic tests and available screening options. RESULTS: Over a period of 27 years, there were 13 939 526 recorded births and 231 227 invasive procedures were performed, resulting in the prenatal diagnosis of 933 SCAs. After the commercial introduction of cfDNA use in 2015, the frequency of invasive procedures decreased significantly (P = 0.03), while the frequency of prenatal SCA detection increased significantly (P = 0.007). Between 2016 and 2021, a high-risk cfDNA result was the indication for 31.4% of detected sex chromosome trisomies, second only to advanced maternal age. CONCLUSIONS: Our findings suggest that the inclusion of SCA in prenatal cfDNA screening tests can increase the prenatal diagnosis of affected individuals. As the benefits of early ascertainment are increasingly recognized, it is essential that healthcare providers are equipped with comprehensive and evidence-based information regarding the associated phenotypic differences and the availability of targeted effective interventions to improve neurodevelopmental and health outcomes for affected individuals. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Samango-Sprouse CA, Grati FR, Brooks M, et al. Incidence of sex chromosome aneuploidy in a prenatal population: 27-year longitudinal study in Northern Italy. Ultrasound Obstet Gynecol. 2023. PMID: 36929222. doi:10.1002/uog.26201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。